Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

被引：78

作者：

Vuky, J

Yu, R

Schwartz, L

Motzer, RJ

机构：

[1] Cornell Univ, Dept Med, Div Solid Tumor Oncol, Genitourinary Oncol Serv, New York, NY USA

[2] Cornell Univ, Dept Radiol, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Med, New York, NY USA

来源：

INVESTIGATIONAL NEW DRUGS | 2002年 / 20卷 / 03期

关键词：

arsenic trioxide; metastatic renal cell carcinoma; phase II trial;

D O I：

10.1023/A:1016270206374

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

引用

页码：327 / 330

页数：4

共 18 条

[1]

CALLEJA EM, 1998, P AN M AM SOC CLIN, V17, pA218

[2]

Chen GQ, 1997, BLOOD, V89, P3345

[3]

Chen GQ, 1996, BLOOD, V88, P1052

[4]

LANDIS SH, 1998, CHEM ABST, V48, P629

[5]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

[6]

2-6

[7] Renal-cell carcinoma [J].

Motzer, RJ ;

Bander, NH ;

Nanus, DM .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (12) :865-875

[8]

Motzer Robert J., 1997, P885

[9] Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients [J].

Niu, C ;

Yan, H ;

Yu, T ;

Sun, HP ;

Liu, JX ;

Li, XS ;

Wu, W ;

Zhang, FQ ;

Chen, Y ;

Zhou, L ;

Li, JM ;

Zeng, XY ;

Yang, RRO ;

Yuan, MM ;

Ren, MY ;

Gu, FY ;

Cao, Q ;

Gu, BW ;

Su, XY ;

Chen, GQ ;

Xiong, SM ;

Zhang, TD ;

Waxman, S ;

Wang, ZY ;

Chen, Z ;

Hu, J ;

Shen, ZX ;

Chen, SJ .

BLOOD, 1999, 94 (10) :3315-3324

[10] Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis [J].

Roboz, GJ ;

Dias, S ;

Lam, G ;

Lane, WJ ;

Soignet, SL ;

Warrell, RP ;

Rafii, S .

BLOOD, 2000, 96 (04) :1525-1530

← 1 2 →